Gevotroline (WY 47,384) is an atypical antipsychotic compound, which was developed for use in the treatment of schizophrenia. Gevotroline has some clinical efficacy, and equal affinity for D2 (dopamine) and 5-HT2 (serotonin) receptors. Gevotroline was also found to have affinity for sigma receptors, which are thought to be involved in certain neuropsychiatric disorders (because of their ability to regulate the hypothalamic-pituitary-adrenal axis), explaining the interest in this compound for therapeutic use in schizophrenia. Gevoltrine is thought to increase activity in the hypothalamic-pituitary-adrenal axis to elevate levels of corticosterone in plasma. Gevotroline is well tolerated and phase II clinical trials have been conducted, but the compound was never marketed.